Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1991 1
2000 2
2001 2
2002 2
2003 3
2004 1
2005 3
2006 7
2007 2
2008 6
2009 7
2010 7
2011 10
2012 15
2013 17
2014 18
2015 29
2016 34
2017 15
2018 27
2019 30
2020 41
2021 44
2022 39
2023 37

Text availability

Article attribute

Article type

Publication date

Search Results

355 results

Results by year

Filters applied: . Clear all The following term was not found in PubMed: Aiboud-Saouli
Page 1
Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study.
Matulonis UA, Lorusso D, Oaknin A, Pignata S, Dean A, Denys H, Colombo N, Van Gorp T, Konner JA, Marin MR, Harter P, Murphy CG, Wang J, Noble E, Esteves B, Method M, Coleman RL. Matulonis UA, et al. J Clin Oncol. 2023 May 1;41(13):2436-2445. doi: 10.1200/JCO.22.01900. Epub 2023 Jan 30. J Clin Oncol. 2023. PMID: 36716407 Free PMC article. Clinical Trial.
Mirvetuximab soravtansine (MIRV) is an antibody-drug conjugate targeting folate receptor alpha (FRalpha). SORAYA is a single-arm, phase II study evaluating efficacy and safety of MIRV in patients with PROC. METHODS: SORAYA enrolled FRalpha-high patients with PROC wh …
Mirvetuximab soravtansine (MIRV) is an antibody-drug conjugate targeting folate receptor alpha (FRalpha). SORAYA is a single-arm, pha …
Inflammation in atherosclerosis.
Taleb S. Taleb S. Arch Cardiovasc Dis. 2016 Dec;109(12):708-715. doi: 10.1016/j.acvd.2016.04.002. Epub 2016 Aug 29. Arch Cardiovasc Dis. 2016. PMID: 27595467 Free article. Review.
Antibody-Drug Conjugates in Gynecologic Cancer.
Karpel HC, Powell SS, Pothuri B. Karpel HC, et al. Am Soc Clin Oncol Educ Book. 2023 May;43:e390772. doi: 10.1200/EDBK_390772. Am Soc Clin Oncol Educ Book. 2023. PMID: 37229642 Free article. Review.
In ovarian cancer, mirvetuximab soravtansine, an ADC targeting alpha-folate receptor (FRalpha), received US Food and Drug Administration (FDA) accelerated approval in November 2022 after data from the single-arm phase III SORAYA trial. A second ADC targeting FRalpha, STRO- …
In ovarian cancer, mirvetuximab soravtansine, an ADC targeting alpha-folate receptor (FRalpha), received US Food and Drug Administration (FD …
Niacin.
Djadjo S, Bajaj T. Djadjo S, et al. 2023 Mar 20. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan–. 2023 Mar 20. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan–. PMID: 31082080 Free Books & Documents.
Mu-CT.
Robinson S, Suomalainen A, Kortesniemi M. Robinson S, et al. Eur J Radiol. 2005 Nov;56(2):185-91. doi: 10.1016/j.ejrad.2005.03.022. Eur J Radiol. 2005. PMID: 16233892 Review.
Dendrimer Prodrugs.
da Silva Santos S, Igne Ferreira E, Giarolla J. da Silva Santos S, et al. Molecules. 2016 May 31;21(6):686. doi: 10.3390/molecules21060686. Molecules. 2016. PMID: 27258239 Free PMC article. Review.
Treatment of hypertension in patients 80 years of age or older.
Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, Stoyanovsky V, Antikainen RL, Nikitin Y, Anderson C, Belhani A, Forette F, Rajkumar C, Thijs L, Banya W, Bulpitt CJ; HYVET Study Group. Beckett NS, et al. N Engl J Med. 2008 May 1;358(18):1887-98. doi: 10.1056/NEJMoa0801369. Epub 2008 Mar 31. N Engl J Med. 2008. PMID: 18378519 Free article. Clinical Trial.
Authors' reply.
Hoskins M, Pearce J, Bethell A, Barbui C, Tol WA, Seedat S, Chen H, Bisson JI. Hoskins M, et al. Br J Psychiatry. 2015 Aug;207(2):177. doi: 10.1192/bjp.207.2.177a. Br J Psychiatry. 2015. PMID: 26243767 No abstract available.
Mirvetuximab soravtansine for platinum-resistant epithelial ovarian cancer.
Porter RL, Matulonis UA. Porter RL, et al. Expert Rev Anticancer Ther. 2023 Jul-Dec;23(8):783-796. doi: 10.1080/14737140.2023.2236793. Epub 2023 Jul 24. Expert Rev Anticancer Ther. 2023. PMID: 37458180 Review.
Mirvetuximab received accelerated approval by the United States Food and Drug Administration (FDA) in November 2022 based on the results of the SORAYA trial, which tested mirvetuximab for the treatment of patients with recurrent platinum resistant HGSOC with high FRalpha e …
Mirvetuximab received accelerated approval by the United States Food and Drug Administration (FDA) in November 2022 based on the results of …
Genetic deficiency of indoleamine 2,3-dioxygenase promotes gut microbiota-mediated metabolic health.
Laurans L, Venteclef N, Haddad Y, Chajadine M, Alzaid F, Metghalchi S, Sovran B, Denis RGP, Dairou J, Cardellini M, Moreno-Navarrete JM, Straub M, Jegou S, McQuitty C, Viel T, Esposito B, Tavitian B, Callebert J, Luquet SH, Federici M, Fernandez-Real JM, Burcelin R, Launay JM, Tedgui A, Mallat Z, Sokol H, Taleb S. Laurans L, et al. Nat Med. 2018 Aug;24(8):1113-1120. doi: 10.1038/s41591-018-0060-4. Epub 2018 Jun 25. Nat Med. 2018. PMID: 29942089
355 results